Information Provided By: 
Fly News Breaks for February 27, 2017
CEMP
Feb 27, 2017 | 09:31 EDT
Janney Capital analyst Debjit Chattopadhyay said the release of data from the phase 3 ABSSI study of fusidic acid "provides a lifeline" for Cempra, though he sees limited differentiation in a crowded segment where the drug would have to compete against generics. The analyst, who thinks the best course forward would be give up on SoliThera in the U.S., "hope for a positive take from the EMA," and consider strategic alternatives, keeps a Neutral rating on Cempra shares and lowered his fair value estimate on the stock to $8 from $10.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
